BASILEA PHARMACEUTICA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.85 CHF | +5.28% |
|
+8.21% | +21.39% |
| May. 03 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
| Apr. 09 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
Presenter SpeechUnknown Analyst (Analysts)Good afternoon. Thank you for coming to 2019 UBS Hea...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
Calendar
2024-08-12
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
42.85
CHF
Average target price
70.58
CHF
Spread / Average Target
+64.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.39% | 570M | |
| +23.37% | 46.71B | |
| +48.83% | 41.8B | |
| -0.94% | 41.52B | |
| -5.86% | 29.55B | |
| +11.29% | 25.78B | |
| -20.92% | 19.26B | |
| +3.20% | 12.14B | |
| -2.67% | 12.08B | |
| +30.23% | 11.98B |
- Stock Market
- Equities
- BSLN Stock
- News Basilea Pharmaceutica AG
- Transcript : Basilea Pharmaceutica AG Presents at UBS Global Healthcare Conference 2019, May-21-2019 02